"杏輝"滴朗眼液

Maa: Taiwan

Kieli: kiina

Lähde: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktiivinen ainesosa:

DEXAMETHASONE PHOSPHATE (SODIUM);;NEOMYCIN (SULFATE)

Saatavilla:

杏輝藥品工業股份有限公司 宜蘭縣冬山鄉中山村中山路84、84之4、84之6、84之7號、冬山鄉中山村新寮路95、95之1、100之7、100之13、100之15、100之16、103、136號 (42042734)

ATC-koodi:

S01CA01

Lääkemuoto:

點眼液劑

Koostumus:

NEOMYCIN (SULFATE) (0812109530) 3.5MG; DEXAMETHASONE PHOSPHATE (SODIUM) (6804008640) 1MG

Kpl paketissa:

塑膠瓶裝;;玻璃瓶裝

luokka:

製　劑

Prescription tyyppi:

須由醫師處方使用

Valmistaja:

杏輝藥品工業股份有限公司 宜蘭縣冬山鄉中山村中山路８４號 TW

Terapeuttinen alue:

dexamethasone and antiinfectives

Käyttöaiheet:

眼瞼敏感症、瞼緣炎、非特異性表層結膜炎、深部角膜炎、帶狀？疹眼炎、水泡性角膜結膜炎、鞏膜角膜炎、結膜炎、虹彩睫狀體炎、虹彩炎、復發性瞼緣潰瘍、角膜潰瘍及角膜損傷

Tuoteyhteenveto:

有效日期: 2024/05/25; 英文品名: DELONE EYE DROP "SINPHAR"

Valtuutus päivämäärä:

1979-12-21

Pakkausseloste

DELONE
Eye Drop.
019915
100
Dexamethasone
1mL
:
Dexamethasone sodium phosphate equivalent to
Dexamethasone phosphate.........................1mg
Neomycin sulfate......................3.5mg(Potency)
Boric acid
Sodium borate
Sodium chloride
Menthol
Benzalkonium chloride
Water for injection
-
1.
2.
3.
4.
5.
6.2
8 4
SINPHAR PHARMACEUTICAL CO., LTD.
84, CHUNG SHAN ROAD, CHUNG SHAN VILLAGE, TUNG - SHAN SHINE, I - LAN,
TAIWAN
[phone]
website
h t t p
//www.sinphar.com
R
cGMP
cGMP
25
Delone combines the antiinflammatory activity of dexamethasone
sodium phosphate with the antimicrobial activity of neomycin, thus
permitting effective management of many disorders of the eye.
Compositions: Each mL contains:
Dexamethasone sodium phosphate equivalent to
Dexamethasone phosphate.........................1mg
Neomycin sulfate.......................3.5mg (potency)
:Boric acid
Sodium borate
Sodium chloride
Menthol
Benzalkonium chloride
Water for injection
Indications: Lid allergy blepharitis, non-specific superficial
keratitis,
deep keratitis, herpes zoster ophthalmicus, phlytenular
keratoconjunctivitis, keratoscleritis, conjunctivitis, iridocyclitis,
iritis, recurrent marginal ulceration, keratohelcosis, corneal
injury.
Dosage and administration:
Instill one or two drops of ophthalmic solution into the
conjunctival sac every hour during the day and every two
hours during the night as initial therapy. When a favorable
response is observed, reduce dosage to one drop every
four hours. Later, further reduction in dosage to one drop
three or four times daily many suffice to control symptoms.
Precautions:
(1) If infection do not respond promptly, ophthalmic
solution should be discontinued until the infection
has been adequately controlled by other measures.
(2) In stubborn cases of anterior segment eye disease and
the deeper ocular structures are involved, systemic
adrenocortical hormone therapy may be required.
(3) Hereditary and degenerative eye disease in general
do not show any response to treatment with this
preparation.
(4) It s